ECPAS

Across TCGA pan-cancer cohorts, ECPAS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ECPAS data layer compared with 26 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ECPAS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ECPAS expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where ECPAS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.381	0.951	.006	12	view →
HNSC	OS	Median	IV	0.937	0.727	.020	7	view →
LUAD	DFS	Quartile	III,IV	0.736	0.252	.037	3	view →
GBM	DFS	Median	All	0.661	0.767	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ECPAS–PDAC (OS)

Open the PDAC breakdown →